Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)
July 11, 2025 16:30 ET | Source: Ultragenyx Pharmaceutical Inc. Complete Response…
AeC Receives Frost & Sullivan’s 2025 Brazilian Company of the Year Award for Excellence in Customer Experience Management
The company is recognized for innovation, operational excellence, and customer-centric digital transformation…
Drger Receives Frost & Sullivan’s 2025 Global Company of the Year Recognition for Excellence in Respiratory Devices Innovation
Dräger recognized for pioneering innovations in respiratory care, delivering measurable improvements in…
TP Receives Frost & Sullivan’s 2025 North American Company of the Year Recognition for Excellence in Secure Innovation
Frost & Sullivan recognizes TP's AI-powered cybersecurity innovation, market leadership, and customer trust…
Gozellix Receives Permanent HCPCS Code
MELBOURNE, Australia and INDIANAPOLIS, July 10, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals…
NTT TechnoCross Receives Frost & Sullivan’s 2025 Japan Company of the Year Recognition for Leadership in Privileged Access Management
The company is recognized for pioneering innovation and customer-centric security solutions in…
Ubiquity Receives Frost & Sullivan’s 2025 North American Transformational Innovation Leadership Award for Excellence in Customer Experience Management
Recognized for transformational innovation and delivering breakthrough customer experience solutions through advanced…
Basilea receives USD 39 million funding under BARDA agreement to continue to advance novel antifungals fosmanogepix and BAL2062
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, July 08,…
Fictiv Receives Frost & Sullivan’s 2025 Global Supply Chain for Custom Mechanicals Technology Innovation Leadership Recognition
Recognized for its innovative approach to global supply chain orchestration, delivering customer…
AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer
PRESS RELEASE MASITINIB RECEIVES FDA AND EMA AUTHORIZATION FOR CONFIRMATORY PHASE 3…
